Literature DB >> 17205459

Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection.

Davey Smith1, Niousha Moini, Rick Pesano, Edward Cachay, Heidi Aiem, Yolanda Lie, Douglas Richman, Susan Little.   

Abstract

In clinical settings, we have found a high rate of human immunodeficiency virus (HIV) drug resistance among antiretroviral-naive patients for whom the duration of infection was unknown. These high rates were most likely the result of both transmitted resistance and informal antiretroviral use, and they suggest that routine resistance testing among antiretroviral-naive patients would be a cost-effective clinical practice.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17205459     DOI： 10.1086/510748

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

1.  Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.

Authors:  Lin Liu; Susanne May; Douglas D Richman; Frederick M Hecht; Martin Markowitz; Eric S Daar; Jean-Pierre Routy; Joseph B Margolick; Ann C Collier; Christopher H Woelk; Susan J Little; Davey M Smith
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

2.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Authors:  Virginie Supervie; J Gerardo García-Lerma; Walid Heneine; Sally Blower
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 3.  Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Authors:  Julie E Myers; Barbara S Taylor; Rita A Rojas Fermín; Emily Virginia Reyes; Catherine Vaughan; Lina José; Carmen Javier; Ramona Franco Estévez; Yeycy Donastorg Cabral; Arelis Batista; Yolanda Lie; Eoin Coakley; Scott M Hammer; Karen Brudney
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

4.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

5.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

6.  A public health model for the molecular surveillance of HIV transmission in San Diego, California.

Authors:  Davey M Smith; Susanne J May; Samantha Tweeten; Lydia Drumright; Mary E Pacold; Sergei L Kosakovsky Pond; Rick L Pesano; Yolanda S Lie; Douglas D Richman; Simon D W Frost; Christopher H Woelk; Susan J Little
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

7.  Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Authors:  Vinod Trivedi; Jana Von Lindern; Miguel Montes-Walters; Daniel R Rojo; Elisabeth J Shell; Neil Parkin; William A O'Brien; Monique R Ferguson
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

8.  Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.

Authors:  Pedro M M Mesquita; Sarah S Wilson; Philippe Manlow; Lucia Fischetti; Marla J Keller; Betsy C Herold; Robin J Shattock
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

9.  Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.

Authors:  Theppharit Panichsillapakit; Davey M Smith; Joel O Wertheim; Douglas D Richman; Susan J Little; Sanjay R Mehta
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

10.  Nevirapine inhibits the anti-HIV activity of CD8+ cells.

Authors:  Lianxing Liu; Lin Wang; Liusheng Huang; Vincent Siu; Fernando Teque; Francesca T Aweeka; Jay A Levy
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.